A Phase 3 interventional study of Ruxolitinib Cream in Atopic Dermatitis (AD), sponsored by Incyte Corporation. Completed at 38 sites in 3 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 3, and was the 10th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 77 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 3 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
17 studies in Dermatitis, Atopic by Incyte Corporation: 2 open now, 3 under way, 1 of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 3, and was the 10th registered.
Incyte Corporation’s Dermatitis, Atopic studies by the year they started, since 2017.
1 of the studies testing ruxolitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661979Wake Forest University Health SciencesOpzelura Experience Study | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 17 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
The study comprises of a 8 week continuous treatment period followed by 44 week Long Term Safety (LTS) period and 30 days safety follow up period. During Continuous treatment period all lesions identified at baseline will be treated and during LTS period only active lesions will be treated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following clinical laboratory test results at screening:
Total > 1.5 × ULN with the exception of Gilbert disease. c. Estimated \< 30 mL/min/1.73 m2 (using the CKD Epidemiology Collaboration equation).
d. Positive serology test results for antibody. e. Any other clinically significant laboratory result that, in the opinion of the investigator, poses a significant risk to the participant.
Use of any of the following treatments within the indicated before baseline:
2 weeks - immunizations with ; sedating antihistamines, unless on long-term stable regimen (nonsedating antihistamines are permitted).
Note: Live-attenuated vaccines are not recommended during the CT period. Note: COVID-19 vaccination is allowed.
Note: Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study.
Further exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
Drug: Ruxolitinib Cream
Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
Also known as: INCB18424 cream
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream.
Time frame: up to 462 days
Number of Participants With ≥Grade 3 TEAEs
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 462 days
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuk), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.
Time frame: up to Week 8
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Basophil, Eosinophil, Leukocyte, Lymphocyte, Monocyte, Neutrophil, and Platelet Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Baso/Leuko, Eosino/Leuko, Lymphocyte/Leuko, Monocyte/Leuko, and Neutro/Leuko Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuko), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Mean Corpuscular Volume and Mean Platelet Volume Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Erythrocyte Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hematocrit Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Hemoglobin Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.
Time frame: from Week 9 up to Week 52 (44 weeks)
CT Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) were measured in units per liter.
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).
Time frame: up to Week 8
CT Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).
Time frame: up to Week 8
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline ALT, ALP, AST, CL, and LDH Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. ALT, ALP, AST, CK, and LDH were measured in units per liter.
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Albumin Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Bilirubin, Creatinine, and Direct Bilirubin Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, and Urea Nitrogen Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).
Time frame: from Week 9 up to Week 52 (44 weeks)
LTS Period: Number of Participants With a Worst Abnormal Post-Baseline Creatinine Clearance Value of Low, Normal, High, Low and High, and Missing
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).
Time frame: from Week 9 up to Week 52 (44 weeks)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 8, 44, and 52
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 8, 44, and 52
Change From Baseline in Pulse at Weeks 8, 44, and 52
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 8, 44, and 52
Change From Baseline in Respiration Rate at Weeks 8, 44, and 52
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 8, 44, and 52
Change From Baseline in Body Temperature at Weeks 8, 44, and 52
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 8, 44, and 52
Change From Baseline in Height at Weeks 8 and 52
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 8 and 52
Change From Baseline in Weight at Weeks 8 and 52
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 8 and 52
Plasma Concentration of Ruxolitinib
Blood samples were drawn to assess plasma concentration.
Time frame: prior to study cream application at Weeks 2 and 4
| Milestone | Ruxolitinib 1.5% Cream BID |
|---|---|
| Started | 103 |
| Completed | 92 |
| Not completed | 11 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Protocol-specified withdrawal criterion met | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Milestone | Ruxolitinib 1.5% Cream BID |
|---|---|
| Started | 92 |
| Completed | 61 |
| Not completed | 31 |
| Withdrew: Lost to follow-up | 12 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Protocol-specified withdrawal criterion met | 1 |
| Withdrew: Withdrawal by subject | 12 |
| Withdrew: Withdrawal by sponsor | 2 |
| Withdrew: Unable to attend the follow-up visit | 1 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 42 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and up to 30 days after the last application of study cream. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Number of Participants With ≥Grade 3 TEAEs | 3 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Basophils, low | 0 |
| Basophils, normal | 94 |
| Basophils, high | 1 |
| Basophils, low and high | 0 |
| Basophils, missing | 8 |
| Eosinophils, low | 0 |
| Eosinophils, normal | 83 |
| Eosinophils, high | 19 |
| Eosinophils, low and high | 0 |
| Eosinophils, missing | 1 |
| Leukocytes, low | 18 |
| Leukocytes, normal | 83 |
| Leukocytes, high | 1 |
| Leukocytes, low and high | 0 |
| Leukocytes, missing | 1 |
| Lymphocytes, low | 7 |
| Lymphocytes, normal | 95 |
| Lymphocytes, high | 0 |
| Lymphocytes, low and high | 0 |
| Lymphocytes, missing | 1 |
| Monocytes, low | 0 |
| Monocytes, normal | 92 |
| Monocytes, high | 10 |
| Monocytes, low and high | 0 |
| Monocytes, missing | 1 |
| Neutrophils, low | 13 |
| Neutrophils, normal | 87 |
| Neutrophils, high | 2 |
| Neutrophils, low and high | 0 |
| Neutrophils, missing | 1 |
| Platelets, low | 5 |
| Platelets, normal | 75 |
| Platelets, high | 21 |
| Platelets, low and high | 1 |
| Platelets, missing | 1 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuk), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Basophils/leukocytes, low | 0 |
| Basophils/leukocytes, normal | 84 |
| Basophils/leukocytes, high | 18 |
| Basophils/leukocytes, low and high | 0 |
| Basophils/leukocytes, missing | 1 |
| Eosinophils/leukocytes, low | 0 |
| Eosinophils/leukocytes, normal | 73 |
| Eosinophils/leukocytes, high | 29 |
| Eosinophils/leukocytes, low and high | 0 |
| Eosinophils/leukocytes, missing | 1 |
| Lymphocytes/leukocytes, low | 29 |
| Lymphocytes/leukocytes, normal | 47 |
| Lymphocytes/leukocytes, high | 22 |
| Lymphocytes/leukocytes, low and high | 4 |
| Lymphocytes/leukocytes, missing | 1 |
| Monocytes/leukocytes, low | 3 |
| Monocytes/leukocytes, normal | 94 |
| Monocytes/leukocytes, high | 5 |
| Monocytes/leukocytes, low and high | 0 |
| Monocytes/leukocytes, missing | 1 |
| Neutrophils/leukocytes, low | 6 |
| Neutrophils/leukocytes, normal | 66 |
| Neutrophils/leukocytes, high | 30 |
| Neutrophils/leukocytes, low and high | 0 |
| Neutrophils/leukocytes, missing | 1 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Erythrocyte mean corpuscular volume, low | 3 |
| Erythrocyte mean corpuscular volume, normal | 88 |
| Erythrocyte mean corpuscular volume, high | 11 |
| Erythrocyte mean corpuscular volume, low and high | 0 |
| Erythrocyte mean corpuscular volume, missing | 1 |
| Mean platelet volume, low | 5 |
| Mean platelet volume, normal | 97 |
| Mean platelet volume, high | 0 |
| Mean platelet volume, low and high | 0 |
| Mean platelet volume, missing | 1 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 14 |
| Normal | 66 |
| High | 22 |
| Low and high | 0 |
| Missing | 1 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 2 |
| Normal | 88 |
| High | 12 |
| Low and high | 0 |
| Missing | 1 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 19 |
| Normal | 79 |
| High | 4 |
| Low and high | 0 |
| Missing | 1 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils, and platelets were measured in 10\^9 cells per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Basophils, low | 0 |
| Basophils, normal | 85 |
| Basophils, high | 2 |
| Basophils, low and high | 0 |
| Basophils, missing | 5 |
| Eosinophils, low | 0 |
| Eosinophils, normal | 63 |
| Eosinophils, high | 25 |
| Eosinophils, low and high | 0 |
| Eosinophils, missing | 4 |
| Leukocytes, low | 20 |
| Leukocytes, normal | 62 |
| Leukocytes, high | 6 |
| Leukocytes, low and high | 0 |
| Leukocytes, missing | 4 |
| Lymphocytes, low | 5 |
| Lymphocytes, normal | 82 |
| Lymphocytes, high | 1 |
| Lymphocytes, low and high | 0 |
| Lymphocytes, missing | 4 |
| Monocytes, low | 0 |
| Monocytes, normal | 75 |
| Monocytes, high | 13 |
| Monocytes, low and high | 0 |
| Monocytes, missing | 4 |
| Neutrophils, low | 12 |
| Neutrophils, normal | 66 |
| Neutrophils, high | 10 |
| Neutrophils, low and high | 0 |
| Neutrophils, missing | 4 |
| Platelets, low | 3 |
| Platelets, normal | 60 |
| Platelets, high | 25 |
| Platelets, low and high | 0 |
| Platelets, missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Basophils (baso)/leukocytes (leuko), eosinophils (eosino)/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, and neutrophils (neutro)/leukocytes were measured as a percentage.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Basophils/leukocytes, low | 0 |
| Basophils/leukocytes, normal | 67 |
| Basophils/leukocytes, high | 21 |
| Basophils/leukocytes, low and high | 0 |
| Basophils/leukocytes, missing | 4 |
| Eosinophils/leukocytes, low | 0 |
| Eosinophils/leukocytes, normal | 49 |
| Eosinophils/leukocytes, high | 39 |
| Eosinophils/leukocytes, low and high | 0 |
| Eosinophils/leukocytes, missing | 4 |
| Lymphocytes/leukocytes, low | 39 |
| Lymphocytes/leukocytes, normal | 29 |
| Lymphocytes/leukocytes, high | 18 |
| Lymphocytes/leukocytes, low and high | 2 |
| Lymphocytes/leukocytes, missing | 4 |
| Monocytes/leukocytes, low | 13 |
| Monocytes/leukocytes, normal | 68 |
| Monocytes/leukocytes, high | 7 |
| Monocytes/leukocytes, low and high | 0 |
| Monocytes/leukocytes, missing | 4 |
| Neutrophils/leukocytes, low | 8 |
| Neutrophils/leukocytes, normal | 43 |
| Neutrophils/leukocytes, high | 37 |
| Neutrophils/leukocytes, low and high | 0 |
| Neutrophils/leukocytes, missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocyte mean corpuscular volume and mean platelet volume were measured in femtoliters.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Erythrocyte mean corpuscular volume, low | 4 |
| Erythrocyte mean corpuscular volume, normal | 56 |
| Erythrocyte mean corpuscular volume, high | 28 |
| Erythrocyte mean corpuscular volume, low and high | 0 |
| Erythrocyte mean corpuscular volume, missing | 4 |
| Mean platelet volume, low | 11 |
| Mean platelet volume, normal | 77 |
| Mean platelet volume, high | 0 |
| Mean platelet volume, low and high | 0 |
| Mean platelet volume, missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Erythrocytes were measured in 10\^12/Liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 19 |
| Normal | 42 |
| High | 26 |
| Low and high | 1 |
| Missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hematocrit was measured in liters of red blood cells per liter of blood (L/L).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 2 |
| Normal | 49 |
| High | 37 |
| Low and high | 0 |
| Missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Hemoglobin was measured in grams per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 26 |
| Normal | 55 |
| High | 7 |
| Low and high | 0 |
| Missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) were measured in units per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| ALT, low | 0 |
| ALT, normal | 100 |
| ALT, high | 3 |
| ALT, low and high | 0 |
| ALT, missing | 0 |
| ALP, low | 14 |
| ALP, normal | 89 |
| ALP, high | 0 |
| ALP, low and high | 0 |
| ALP, missing | 0 |
| AST, low | 0 |
| AST, normal | 102 |
| AST, high | 1 |
| AST, low and high | 0 |
| AST, missing | 0 |
| CK, low | 3 |
| CK, normal | 77 |
| CK, high | 22 |
| CK, low and high | 1 |
| CK, missing | 0 |
| LDH, low | 7 |
| LDH, normal | 91 |
| LDH, high | 5 |
| LDH, low and high | 0 |
| LDH, missing | 0 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 0 |
| Normal | 23 |
| High | 80 |
| Low and high | 0 |
| Missing | 0 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Bilirubin, low | 31 |
| Bilirubin, normal | 68 |
| Bilirubin, high | 4 |
| Bilirubin, low and high | 0 |
| Bilirubin, missing | 0 |
| Creatinine, low | 54 |
| Creatinine, normal | 49 |
| Creatinine, high | 0 |
| Creatinine, low and high | 0 |
| Creatinine, missing | 0 |
| Direct bilirubin, low | 0 |
| Direct bilirubin, normal | 4 |
| Direct bilirubin, high | 0 |
| Direct bilirubin, low and high | 0 |
| Direct bilirubin, missing | 99 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Calcium, low | 0 |
| Calcium, normal | 84 |
| Calcium, high | 19 |
| Calcium, low and high | 0 |
| Calcium, missing | 0 |
| Chloride, low | 52 |
| Chloride, normal | 51 |
| Chloride, high | 0 |
| Chloride, low and high | 0 |
| Chloride, missing | 0 |
| Glucose, low | 13 |
| Glucose, normal | 86 |
| Glucose, high | 4 |
| Glucose, low and high | 0 |
| Glucose, missing | 0 |
| Phosphate, low | 0 |
| Phosphate, normal | 82 |
| Phosphate, high | 21 |
| Phosphate, low and high | 0 |
| Phosphate, missing | 0 |
| Potassium, low | 0 |
| Potassium, normal | 80 |
| Potassium, high | 23 |
| Potassium, low and high | 0 |
| Potassium, missing | 0 |
| Sodium, low | 8 |
| Sodium, normal | 93 |
| Sodium, high | 1 |
| Sodium, low and high | 1 |
| Sodium, missing | 0 |
| Urea nitrogen, low | 2 |
| Urea nitrogen, normal | 86 |
| Urea nitrogen, high | 15 |
| Urea nitrogen, low and high | 0 |
| Urea nitrogen, missing | 0 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 0 |
| Normal | 2 |
| High | 4 |
| Low and high | 0 |
| Missing | 97 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. ALT, ALP, AST, CK, and LDH were measured in units per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| ALT, low | 5 |
| ALT, normal | 78 |
| ALT, high | 5 |
| ALT, low and high | 0 |
| ALT, missing | 4 |
| ALP, low | 14 |
| ALP, normal | 69 |
| ALP, high | 5 |
| ALP, low and high | 0 |
| ALP, missing | 4 |
| AST, low | 2 |
| AST, normal | 82 |
| AST, high | 4 |
| AST, low and high | 0 |
| AST, missing | 4 |
| CK, low | 5 |
| CK, normal | 56 |
| CK, high | 27 |
| CK, low and high | 0 |
| CK, missing | 4 |
| LDH, low | 9 |
| LDH, normal | 72 |
| LDH, high | 7 |
| LDH, low and high | 0 |
| LDH, missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Albumin was measured in grams per liter.
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 0 |
| Normal | 19 |
| High | 69 |
| Low and high | 0 |
| Missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Bilirubin, creatinine, and direct bilirubin were measured in micromoles per liter (µmol/L).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Bilirubin, low | 40 |
| Bilirubin, normal | 43 |
| Bilirubin, high | 5 |
| Bilirubin, low and high | 0 |
| Bilirubin, missing | 4 |
| Creatinine, low | 58 |
| Creatinine, normal | 30 |
| Creatinine, high | 0 |
| Creatinine, low and high | 0 |
| Creatinine, missing | 4 |
| Direct bilirubin, low | 0 |
| Direct bilirubin, normal | 4 |
| Direct bilirubin, high | 0 |
| Direct bilirubin, low and high | 0 |
| Direct bilirubin, missing | 88 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Calcium, chloride, glucose, phosphate, potassium, sodium, and urea nitrogen were measured in millimoles per liter (mmol/L).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Calcium, low | 2 |
| Calcium, normal | 72 |
| Calcium, high | 14 |
| Calcium, low and high | 0 |
| Calcium, missing | 4 |
| Chloride, low | 54 |
| Chloride, normal | 34 |
| Chloride, high | 0 |
| Chloride, low and high | 0 |
| Chloride, missing | 4 |
| Glucose, low | 12 |
| Glucose, normal | 72 |
| Glucose, high | 4 |
| Glucose, low and high | 0 |
| Glucose, missing | 4 |
| Phosphate, low | 1 |
| Phosphate, normal | 62 |
| Phosphate, high | 25 |
| Phosphate, low and high | 0 |
| Phosphate, missing | 4 |
| Potassium, low | 1 |
| Potassium, normal | 66 |
| Potassium, high | 21 |
| Potassium, low and high | 0 |
| Potassium, missing | 4 |
| Sodium, low | 17 |
| Sodium, normal | 70 |
| Sodium, high | 0 |
| Sodium, low and high | 1 |
| Sodium, missing | 4 |
| Urea nitrogen, low | 4 |
| Urea nitrogen, normal | 65 |
| Urea nitrogen, high | 19 |
| Urea nitrogen, low and high | 0 |
| Urea nitrogen, missing | 4 |
Low: participants with ≥1 low value but not any high values. High: participants with ≥1 high value but not any low values. Normal: participants without any low or high values. Low and high: participants with both low and high values. Creatinine clearance was measured in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2).
| Participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Low | 0 |
| Normal | 10 |
| High | 11 |
| Low and high | 0 |
| Missing | 71 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| millimeters of mercury (mmHg) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline, SBP | 112.7 ± 11.14 |
| Change from Baseline at Week 8, SBP | 0.6 ± 10.01 |
| Change from Baseline at Week 44, SBP | -1.4 ± 11.10 |
| Change from Baseline at Week 52, SBP | 1.0 ± 10.77 |
| Baseline, DBP | 71.0 ± 8.03 |
| Change from Baseline at Week 8, DBP | 0.2 ± 8.35 |
| Change from Baseline at Week 44, DBP | 0.1 ± 9.31 |
| Change from Baseline at Week 52, DBP | 1.0 ± 8.04 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| beats per minute | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 78.8 ± 12.71 |
| Change from Baseline at Week 8 | 0.5 ± 11.23 |
| Change from Baseline at Week 44 | -0.6 ± 11.69 |
| Change from Baseline at Week 52 | -0.4 ± 12.18 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| breaths per minute | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 16.1 ± 2.50 |
| Change from Baseline at Week 8 | 0.7 ± 6.91 |
| Change from Baseline at Week 44 | -0.5 ± 1.91 |
| Change from Baseline at Week 52 | -0.1 ± 1.88 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| degrees Celsius | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 36.5 ± 0.42 |
| Change from Baseline at Week 8 | 0.0 ± 0.40 |
| Change from Baseline at Week 44 | 0.1 ± 0.43 |
| Change from Baseline at Week 52 | 0.1 ± 0.44 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| centimeters | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 165.1 ± 9.88 |
| Change from Baseline at Week 8 | 0.7 ± 1.20 |
| Change from Baseline at Week 52 | 3.1 ± 3.31 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| kilograms | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 65.0 ± 18.25 |
| Change from Baseline at Week 8 | 0.9 ± 3.11 |
| Change from Baseline at Week 52 | 3.8 ± 7.01 |
Blood samples were drawn to assess plasma concentration.
| nanomoles per liter (nM) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Week 2 | 21.4 ± 27.7 |
| Week 4 | 24.6 ± 38.2 |
Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to approximately 20 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib 1.5% Cream BID | 0/103 (0%) | 2/103 (1.9%) | 20/103 (19.4%) |
| Event | Ruxolitinib 1.5% Cream BID |
|---|---|
| DepressionPsychiatric disorders | 1/103 |
| Pneumonia mycoplasmalInfections and infestations | 1/103 |
| Event | Ruxolitinib 1.5% Cream BID |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 11/103 |
| NasopharyngitisInfections and infestations | 9/103 |
| Age, Continuous(years) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Mean | 14.3 ± 1.64 |
| Sex: Female, Male(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Female | 56 |
| Male | 47 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Hispanic or Latino | 23 |
| Not Hispanic or Latino | 80 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| White/Caucasian | 46 |
| Black/African-American | 31 |
| Asian | 18 |
| Native Hawaiian/Pacific Islander | 2 |
| Unknown | 1 |
| Asian/White | 1 |
| Middle Eastern (Arab) | 1 |
| East Indian | 1 |
| White/Black | 1 |
| Asian, Dominican, Cuban | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Sep 2022 to primary completion in May 2024, 20 months.
Results were first posted in Jun 2025, 1 year 1 month after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 20 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib